{
    "ticker": "RPRX",
    "name": "Repare Therapeutics Inc.",
    "description": "Repare Therapeutics Inc. is a biotechnology company focused on developing precision medicine for cancer treatment. Founded in 2016, Repare leverages its proprietary platform to identify and develop novel therapeutics that target tumor vulnerabilities associated with DNA damage repair (DDR). The company's mission is to revolutionize cancer care by delivering innovative therapies that are designed to improve patient outcomes. Repare's lead product candidate, RP-3500, is currently in clinical trials and targets tumors with specific genetic alterations, aiming to provide effective treatment options for patients with limited alternatives. The company's research and development efforts are built on a deep understanding of cancer biology and a commitment to advancing the field of oncology. Repare is dedicated to harnessing the power of genetic insights to create transformative treatments that can change the cancer treatment paradigm. With a strong pipeline and strategic collaborations with leading research institutions, Repare is positioned to make significant contributions to the field of cancer therapeutics.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Montreal, Quebec, Canada",
    "founded": "2016",
    "website": "https://www.reparetherapeutics.com",
    "ceo": "Leigh A. G. C. B. Regan",
    "social_media": {
        "twitter": "https://twitter.com/RepareTx",
        "linkedin": "https://www.linkedin.com/company/repare-therapeutics/"
    },
    "investor_relations": "https://www.reparetherapeutics.com/investors",
    "key_executives": [
        {
            "name": "Leigh A. G. C. B. Regan",
            "position": "CEO"
        },
        {
            "name": "Katherine L. M. O'Brien",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapeutics",
            "products": [
                "RP-3500"
            ]
        }
    ],
    "seo": {
        "meta_title": "Repare Therapeutics Inc. | Precision Medicine for Cancer",
        "meta_description": "Explore Repare Therapeutics Inc., a biotechnology company focused on precision medicine for cancer treatment. Discover innovative therapies targeting DNA damage repair.",
        "keywords": [
            "Repare Therapeutics",
            "Cancer Treatment",
            "Precision Medicine",
            "Biotechnology",
            "RP-3500"
        ]
    },
    "faq": [
        {
            "question": "What does Repare Therapeutics focus on?",
            "answer": "Repare Therapeutics focuses on developing precision medicine for cancer treatment, particularly targeting DNA damage repair vulnerabilities."
        },
        {
            "question": "Who is the CEO of Repare Therapeutics?",
            "answer": "Leigh A. G. C. B. Regan is the CEO of Repare Therapeutics Inc."
        },
        {
            "question": "Where is Repare Therapeutics headquartered?",
            "answer": "Repare Therapeutics is headquartered in Montreal, Quebec, Canada."
        },
        {
            "question": "What is RP-3500?",
            "answer": "RP-3500 is Repare's lead product candidate that targets tumors with specific genetic alterations."
        },
        {
            "question": "When was Repare Therapeutics founded?",
            "answer": "Repare Therapeutics was founded in 2016."
        }
    ],
    "competitors": [
        "AZN",
        "MRNA",
        "BMY",
        "REGN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "JNJ"
    ]
}